Elvinix Announces Exclusive License Agreement With Zealand Pharma, Granting Elvinix Rights To Develop And Commercialize Zealand’s GLP-1/Gastrin Dual-Agonist Peptide Portfolio
The company plans to advance the licensed GLP-1/gastrin dual-agonist peptide portfolio from Zealand Pharma as a disease-modifying therapy to regenerate and protect endogenous beta-cell mass in patients with type 1
Share
Why It Matters
Elvinix got permission to develop and sell Zealand's new medicine. This shows Elvinix is betting on a fresh approach to treat type 1 diabetes.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.